Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by Gorf79on Aug 16, 2022 10:41am
134 Views
Post# 34899237

RE:RE:Financing

RE:RE:Financing

Some very valid suggestions MM.

However none allow for insiders to acquire more pathetically cheap shares. 

The easiest and most efficient way to do so is another criminally cheap financing... I hope they won't but it is sure looking that way.

BTW didn't the CEO suggest 2023 would see "many multiples" of the equally misearable 2022 share price. We can chalk that up to the well visited ludicrous joke column that has been the hallmark of Spectral management for decades.

I had thought things had changed with the new regime but not when GREED comes into play.

<< Previous
Bullboard Posts
Next >>